Group 1 - The company Yiteng Jiahe (06998) announced a share buyback on February 9, 2026, spending HKD 1.4085 million to repurchase 508,500 shares at a price of HKD 2.77 per share [1]

公司名稱： 亿腾嘉和醫藥集團有限公司 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 呈交日期： 2026年2月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06998 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry, indicating a positive outlook for investment opportunities in this sector [3]. Core Insights - The commercialization of Antibody-Drug Conjugates (ADC) is accelerating, with 20 ADC drugs approved globally, and 6 of them consistently generating over $1 billion in revenue for two consecutive years. The competition in the ADC market is entering a new phase, with approximately 60 ADC drugs currently in clinical phase 3 or awaiting market approval [6][30]. - Domestic innovative pharmaceutical companies are adopting various strategies for ADC capacity layout, with companies like Rongchang Biopharma transitioning from outsourcing to in-house production, while others like Kelong Biotechnology are building their own production bases [6][31]. - The recent revision of the "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" supports segmented contract manufacturing and commercial-scale drug sales, providing a foundation for ADC commercialization partnerships [6][32]. Market Performance - The pharmaceutical index rose by 0.14% this week, outperforming the CSI 300 index by 1.47 percentage points, ranking 15th in industry performance [10]. - Since the beginning of 2026, the pharmaceutical index has increased by 3.28%, again outperforming the CSI 300 index by 2.99 percentage points, ranking 23rd [10]. - The best-performing sub-sector this week was Traditional Chinese Medicine, which increased by 2.56%, while Chemical Pharmaceuticals and Biological Products saw declines of 0.62% and 1.82%, respectively [15][17]. Stock Performance - Among A-share pharmaceutical stocks, the top five performers this week were Guangshengtang (+29.83%), Haixiang Pharmaceutical (+18.64%), and Meidixi (+18.04%) [20]. - In the Hong Kong market, the top performers included Yiteng Jiahe (+14%) and Kedi-B (+9.96%), with 38 out of 116 pharmaceutical stocks rising, representing 32.76% [24][25]. Industry News and Policies - The inclusion of implantable brain-machine interfaces in the category of Class III medical devices marks a significant regulatory development, indicating a focus on innovative medical technologies [27]. - Novartis has submitted an application for the marketing of Ianalumab in China, a drug targeting various autoimmune diseases, which has shown promising results in clinical trials [27]. - Johnson & Johnson announced the approval of Daratumumab injection for a new combination therapy in China, providing a new treatment option for multiple myeloma patients [28].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [3] Core Insights - The commercialization of ADC (Antibody-Drug Conjugates) is accelerating, with 20 ADC drugs approved globally, and 6 of them have been in the "billion-dollar club" for two consecutive years [30][31] - The report highlights the increasing competition in the ADC sector, with approximately 60 ADC drugs currently in clinical phase 3 and application stages [30] - Domestic innovative pharmaceutical companies are adopting various strategies for ADC capacity layout, with companies like Rongchang Biopharma transitioning from outsourcing to in-house production, while others like Kelong Biotechnology are building their own production bases [31][32] Summary by Sections Market Review - The pharmaceutical index rose by 0.14% this week, outperforming the CSI 300 index by 1.47 percentage points, ranking 15th in industry performance [10] - Year-to-date, the pharmaceutical index has increased by 3.28%, also outperforming the CSI 300 index by 2.99 percentage points, ranking 23rd [10] Individual Stock Performance - In the A-share market, 255 out of 479 pharmaceutical stocks rose, with the top five performers being Guangshengtang (+29.83%), Haixiang Pharmaceutical (+18.64%), and Meidixi (+18.04%) [20] - In the Hong Kong market, 38 out of 116 pharmaceutical stocks rose, with the top performers including Yiteng Jiahe (+14%) and Kedi-B (+9.96%) [24] Industry News and Policies - The newly revised "Regulations on the Implementation of the Drug Administration Law" supports segmented contract manufacturing and commercial-scale drug sales, providing a foundation for ADC commercialization cooperation [32] - Notable industry developments include Novartis's application for Ianalumab in China and Johnson & Johnson's approval of Daratumumab injection for multiple myeloma treatment [27][28] Weekly Insights - The ADC commercialization battle has begun, with a significant increase in demand for ADC production capacity, leading to a supply-demand imbalance [30] - Major CXO companies are expanding ADC production capacity, with companies like WuXi AppTec acquiring East Yao Pharmaceutical to meet rising orders [31]

亿腾嘉和(06998)发布公告，旗下小核酸创新药EDP167II期临床试验成功完成首例受试者给药。 EDP167II期临床试验是一项针对纯合子家族性高胆固醇血症(HoFH)成人患者的多中心、剂量探索、开 放标签的试验，旨在评估EDP167在HoFH患者中的疗效和安全性，其主要终点为首次给药24周后低密度 脂蛋白胆固醇(LDL-C)水平相较基线的变化，预计于2026年第四季度完成主要终点的评估。 ...

智通财经APP讯，亿腾嘉和(06998)发布公告，旗下小核酸创新药EDP167 II期临床试验成功完成首例受 试者给药。 EDP167 II期临床试验是一项针对纯合子家族性高胆固醇血症(HoFH)成人患者的多中心、剂量探索、开 放标签的试验，旨在评估EDP167在HoFH患者中的疗效和安全性，其主要终点为首次给药24周后低密度 脂蛋白胆固醇(LDL-C)水平相较基线的变化，预计于2026年第四季度完成主要终点的评估。 ...

格隆汇2月9日丨亿腾嘉和(06998.HK)发布公告，旗下小核酸创新药EDP167 II期临床试验成功完成首例 受试者给药。EDP167 II期临床试验是一项针对纯合子家族性高胆固醇血症("HoFH")成人患者的多中 心、剂量探索、开放标签的试验，旨在评估EDP167在HoFH患者中的疗效和安全性，其主要终点为首次 给药24周后低密度脂蛋白胆固醇("LDL-C")水平相较基线的变化，预计于2026年第四季度完成主要终点 的评估。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 EDP167 II期臨床試驗是一項針對純合子家族性高膽固醇血症（「HoFH」）成人患者 的多中心、劑量探索、開放標籤的試驗，旨在評估EDP167在HoFH患者中的療效 和安全性，其主要終點為首次給藥24周後低密度脂蛋白膽固醇（「LDL-C」）水平相 較基線的變化，預計於2026年第四季度完成主要終點的評估。 關於EDP167 EDDING GENOR GROUP HOLDINGS LIMITED 億騰嘉和醫藥集團有限公司 （前稱嘉和生物藥業（開曼）控股有限公司） （於開曼群島註冊成立的有限公司） （股份代號：6998） 自願公告 EDP167 II期臨床試驗完成首例受試者給藥 本公告由億騰嘉和醫藥集團有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，以告知本公司股東（「股東」）及潛在投資者有關本集團最新業務更新。 本公司董事（「董事」）會（「董事會」）欣然宣佈，旗下小核酸創新藥EDP167 ...

智通财经APP讯，亿腾嘉和(06998)发布公告，于2026年2月6日，该公司斥资24.99万港元回购9.3万股。 （原标题：亿腾嘉和(06998)2月6日斥资24.99万港元回购9.3万股） ...

格隆汇2月6日丨亿腾嘉和(06998.HK)公告，2月6日耗资25万港元回购9.3万股。 ...